Glaukos

Glaukos

Yahoo Finance • 6 days ago

Stocks To Watch On Wall Street's Radar — Several In Or Near Buy Range

As the market rallies, Raymond James, Tapestry and U.S. Bancorp lead a slew of stocks to watch in or near buy range. Continue Reading... Full story

Yahoo Finance • 12 days ago

Dow Jones Futures: Stock Market Tumbles, Oil Prices Soar On Trump's Iran Threats; Microsoft, Meta, Fortinet Earnings Late

The stock market sold off as oil prices surged on Trump's Iran threats. Microsoft, Meta and Fortinet were key earnings movers late. Continue Reading... Full story

Yahoo Finance • 17 days ago

Next Century Growth Investors exits Bloom Energy, Coherent; adds DigitalOcean in Q2

[Annual report under review] Willie B. Thomas In its Q2 portfolio update, Next Century Growth Investors disclosed nine new positions across three sectors. The industrial additions were Park Aerospace Corp. (PKE [https://seekingalpha.com/... Full story

Yahoo Finance • last month

Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More

Quick Read T-Mobile (TMUS) and Gilead Sciences (GILD) both earned Buy upgrades Monday, with Bank of America and HSBC setting targets of $220 and $155 respectively. Pfizer (PFE) and Datadog (DDOG) both took ratings cuts Monday, though Bern... Full story

Yahoo Finance • 5 months ago

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus, a Sight-Threatening Rare Disease ALISO VIEJO, Calif., March 19, 2026--(BUSINESS WIRE)--Glauko... Full story

Yahoo Finance • 7 months ago

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

Glaukos Corporation GKOS is well-poised for growth on the back of the iDose TR launch and a robust product pipeline. However, stiff competition is a concern. Shares of this Zacks Rank #3 (Hold) company have gained 12.5% so far this year c... Full story

Yahoo Finance • 8 months ago

Sudo Biosciences Appoints Paul Bavier as Chief Legal Counsel

CARMEL, Ind. & LONDON, December 04, 2025--(BUSINESS WIRE)--Sudo Biosciences, ("Sudo"), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced the appoi... Full story

Yahoo Finance • 9 months ago

Why Glaukos Stock Zoomed Almost 14% Higher on Thursday

Key Points The biotech notched a new all-time high for net sales in its third quarter. This growth was powered by sales of its foundational glaucoma products.10 stocks we like better than Glaukos › Glaukos(NYSE: GKOS), a biotech and phar... Full story

Yahoo Finance • 9 months ago

Glaukos outlines $600M–$620M 2026 revenue outlook as Epioxa launch and iDose TR drive growth

Earnings Call Insights: Glaukos Corporation (GKOS) Q3 2025 MANAGEMENT VIEW * CEO Thomas Burns began by highlighting "record third quarter consolidated net sales of $133.5 million, up 38% on a reported basis or 37% on a constant currenc... Full story

Yahoo Finance • 10 months ago

Catalyst Watch: Tesla and Netflix leads an earnings blitz, Samsung event, and delayed CPI

[View from Wall Street, New York City.] U.Ozel.Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. SUN... Full story

Yahoo Finance • 10 months ago

Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting

ALISO VIEJO, Calif., October 14, 2025--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal... Full story

Yahoo Finance • 10 months ago

Glaukos gains as Goldman Sachs initiates at Buy on valuation

[Business on Wall Street in Manhattan] Pgiam/iStock via Getty Images Shares of Glaukos Corporation (NYSE:GKOS [https://seekingalpha.com/symbol/GKOS]) inched higher on Wednesday after Goldman Sachs initiated its coverage with a Buy recomme... Full story

Yahoo Finance • 10 months ago

3 Stocks That May Be Trading Below Estimated Fair Value

As the U.S. stock market navigates through a government shutdown and unexpected private-sector job losses, major indices like the Nasdaq and S&P 500 continue to show resilience, with recent gains bringing them near record highs. In this fl... Full story

Yahoo Finance • 10 months ago

3 Companies That May Be Priced Below Their Estimated Value

As the United States stock market navigates uncertainties such as potential government shutdowns and fluctuating commodity prices, major indices like the Dow Jones, Nasdaq, and S&P 500 have shown resilience with recent gains. In this envir... Full story

Yahoo Finance • 11 months ago

The Math Shows JHSC Can Go To $47

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 11 months ago

Glaukos Corporation (GKOS) Advances Next-Gen Glaucoma and Corneal Therapies, Eyes FDA Approval for Epioxa

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Glaukos Corporation stands seventh among them. Glaukos Corporation (NYSE:GKOS), a leader in ophthalmic pharmaceutical and surgical therapi... Full story

Yahoo Finance • 11 months ago

Three Stocks That May Be Undervalued In August 2025

As of late August 2025, the U.S. stock market is experiencing a period of optimism, with major indices like the S&P 500 and Dow Jones Industrial Average reaching record highs. Amid this bullish environment, identifying undervalued stocks c... Full story

Yahoo Finance • last year

Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30

Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif., July 09, 2025--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the t... Full story

Yahoo Finance • last year

Glaukos receives EU certification for glaucoma surgery devices

ALISO VIEJO, Calif. - Glaukos Corporation (NYSE:GKOS), a $5.67 billion medical device company showing impressive revenue growth of nearly 24% over the last twelve months, has received European Union Medical Device Regulation certification... Full story

Yahoo Finance • last year

NYSE Content Advisory: Pre-Market update + S&P 500 trades within 1% of record

NEW YORK, June 25, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Kristen S... Full story